NFκB signaling, a key regulator of hepatic myofibroblast activation24, was found to be active in MPN BM-MSCs, since the expression of pNFκB subunit p65 was significantly increased in patients compared to HDs (Fig. 4c, d). The gene discussed is NFKB1; the disease is myeloproliferative disorder.